Characterizing Mutational Signatures in Human Cancer Cell Lines Reveals Episodic APOBEC Mutagenesis
Mia Petljak(Wellcome Sanger Institute), Michael R. Stratton(Wellcome Sanger Institute), Kathryn Beal(Wellcome Trust), Jonathan Brammeld(Wellcome Sanger Institute), Keiran Raine(Wellcome Sanger Institute), David Jones(European Bioinformatics Institute), Peter J. Campbell(Wellcome Sanger Institute), Sebastian Großmann(Wellcome Sanger Institute), Burçak Otlu(Middle East Technical University), Jennifer Graham(Wellcome Sanger Institute), Young Seok Ju(Korea Advanced Institute of Science and Technology), Bernardo Rodríguez–Martín(Universidade de Santiago de Compostela), José M. C. Tubío(Wellcome Sanger Institute), Andrew Menzies(Wellcome Sanger Institute), Ilias Georgakopoulos‐Soares(University of California, San Francisco), Ching Chiek Koh(Wellcome Sanger Institute), Shriram G. Bhosle(Wellcome Sanger Institute), Serena Nik‐Zainal(University of Cambridge), Laura P. O’Neill(Wellcome Sanger Institute), Mark Maddison(Wellcome Sanger Institute), Stacey Price(Wellcome Sanger Institute), Ultan McDermott(Wellcome Sanger Institute), Ludmil B. Alexandrov(UC San Diego Health System), Jorge Zamora(Universidade de Santiago de Compostela), Francesco Iorio(Open Targets), Mathew J. Garnett(Wellcome Sanger Institute), Calli Latimer(Wellcome Sanger Institute), Nikita Patel(Emory University), Elizabeth Anderson(Wellcome Sanger Institute), Jon W. Teague(European Bioinformatics Institute), Kevin J. Dawson(Wellcome Sanger Institute), Adam P. Butler(Wellcome Sanger Institute), David C. Wedge(Wellcome Sanger Institute), Sarah O’Meara(Wellcome Sanger Institute), Bee Ling Ng(Wellcome Sanger Institute)
Cited by 446
Related Papers
Mutations of the BRAF gene in human cancer
|Nature|2002|10.7k
Signatures of mutational processes in human cancer
|Nature|2013|10.1k
COSMIC: the Catalogue Of Somatic Mutations In Cancer
|Nucleic Acids Research|2018|5.2k
Drug repurposing: progress, challenges and recommendations
|Nature Reviews Drug Discovery|2018|4.6k
Genomic Classification and Prognosis in Acute Myeloid Leukemia
|New England Journal of Medicine|2016|4.4k